000128762 001__ 128762
000128762 005__ 20240228143346.0
000128762 0247_ $$2doi$$a10.1007/s00401-015-1495-z
000128762 0247_ $$2pmid$$apmid:26493382
000128762 0247_ $$2ISSN$$a0001-6322
000128762 0247_ $$2ISSN$$a1432-0533
000128762 0247_ $$2altmetric$$aaltmetric:4670227
000128762 037__ $$aDKFZ-2017-04777
000128762 041__ $$aeng
000128762 082__ $$a610
000128762 1001_ $$aHerrlinger, Ulrich$$b0
000128762 245__ $$aGliomatosis cerebri: no evidence for a separate brain tumor entity.
000128762 260__ $$aBerlin$$bSpringer$$c2016
000128762 3367_ $$2DRIVER$$aarticle
000128762 3367_ $$2DataCite$$aOutput Types/Journal article
000128762 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1530611508_13131
000128762 3367_ $$2BibTeX$$aARTICLE
000128762 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128762 3367_ $$00$$2EndNote$$aJournal Article
000128762 520__ $$aGliomatosis cerebri (GC) is presently considered a distinct astrocytic glioma entity according to the WHO classification for CNS tumors. It is characterized by widespread, typically bilateral infiltration of the brain involving three or more lobes. Genetic studies of GC have to date been restricted to the analysis of individual glioma-associated genes, which revealed mutations in the isocitrate dehydrogenase 1 (IDH1) and tumor protein p53 (TP53) genes in subsets of patients. Here, we report on a genome-wide analysis of DNA methylation and copy number aberrations in 25 GC patients. Results were compared with those obtained for 105 patients with various types of conventional, i.e., non-GC gliomas including diffuse astrocytic gliomas, oligodendrogliomas and glioblastomas. In addition, we assessed the prognostic role of methylation profiles and recurrent DNA copy number aberrations in GC patients. Our data reveal that the methylation profiles in 23 of the 25 GC tumors corresponded to either IDH mutant astrocytoma (n = 6), IDH mutant and 1p/19q codeleted oligodendroglioma (n = 5), or IDH wild-type glioblastoma including various molecular subgroups, i.e., H3F3A-G34 mutant (n = 1), receptor tyrosine kinase 1 (RTK1, n = 4), receptor tyrosine kinase 2 (classic) (RTK2, n = 2) or mesenchymal (n = 5) glioblastoma groups. Two tumors showed methylation profiles of normal brain tissue due to low tumor cell content. While histological grading (WHO grade IV vs. WHO grade II and III) was not prognostic, the molecular classification as classic/RTK2 or mesenchymal glioblastoma was associated with worse overall survival. Multivariate Cox regression analysis revealed MGMT promoter methylation as a positive prognostic factor. Taken together, DNA-based large-scale molecular profiling indicates that GC comprises a genetically and epigenetically heterogeneous group of diffuse gliomas that carry DNA methylation and copy number profiles closely matching the common molecularly defined glioma entities. These data support the removal of GC as a distinct glioma entity in the upcoming revision of the WHO classification.
000128762 536__ $$0G:(DE-HGF)POF3-319H$$a319H - Addenda (POF3-319H)$$cPOF3-319H$$fPOF III$$x0
000128762 588__ $$aDataset connected to CrossRef, PubMed,
000128762 650_7 $$2NLM Chemicals$$aTumor Suppressor Proteins
000128762 650_7 $$0EC 1.1.1.41$$2NLM Chemicals$$aIsocitrate Dehydrogenase
000128762 650_7 $$0EC 1.1.1.42.$$2NLM Chemicals$$aIDH1 protein, human
000128762 650_7 $$0EC 2.1.1.-$$2NLM Chemicals$$aDNA Modification Methylases
000128762 650_7 $$0EC 2.1.1.63$$2NLM Chemicals$$aMGMT protein, human
000128762 650_7 $$0EC 6.5.1.-$$2NLM Chemicals$$aDNA Repair Enzymes
000128762 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b1$$udkfz
000128762 7001_ $$aGlas, Martin$$b2
000128762 7001_ $$aHattingen, Elke$$b3
000128762 7001_ $$aGramatzki, Dorothee$$b4
000128762 7001_ $$aStuplich, Moritz$$b5
000128762 7001_ $$aFelsberg, Jörg$$b6
000128762 7001_ $$aBähr, Oliver$$b7
000128762 7001_ $$aGielen, Gerrit H$$b8
000128762 7001_ $$aSimon, Matthias$$b9
000128762 7001_ $$aWiewrodt, Dorothee$$b10
000128762 7001_ $$aSchabet, Martin$$b11
000128762 7001_ $$0P:(DE-He78)744146d3b5a3df1e0ac555e5bf1ee5cc$$aHovestadt, Volker$$b12$$udkfz
000128762 7001_ $$0P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aCapper, David$$b13$$udkfz
000128762 7001_ $$aSteinbach, Joachim P$$b14
000128762 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b15$$udkfz
000128762 7001_ $$0P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c$$aLichter, Peter$$b16$$udkfz
000128762 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b17$$udkfz
000128762 7001_ $$aWeller, Michael$$b18
000128762 7001_ $$0P:(DE-HGF)0$$aReifenberger, Guido$$b19$$eLast author
000128762 773__ $$0PERI:(DE-600)1458410-4$$a10.1007/s00401-015-1495-z$$gVol. 131, no. 2, p. 309 - 319$$n2$$p309 - 319$$tActa neuropathologica$$v131$$x1432-0533$$y2016
000128762 909CO $$ooai:inrepo02.dkfz.de:128762$$pVDB
000128762 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000128762 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)744146d3b5a3df1e0ac555e5bf1ee5cc$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000128762 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000128762 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000128762 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000128762 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000128762 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000128762 9131_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000128762 9141_ $$y2016
000128762 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000128762 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA NEUROPATHOL : 2015
000128762 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128762 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128762 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128762 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000128762 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000128762 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128762 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128762 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128762 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128762 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000128762 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128762 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bACTA NEUROPATHOL : 2015
000128762 9201_ $$0I:(DE-He78)L401-20160331$$kL401$$lDKTK Essen$$x0
000128762 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000128762 9201_ $$0I:(DE-He78)L501-20160331$$kL501$$lDKTK Frankfurt$$x2
000128762 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x3
000128762 9201_ $$0I:(DE-He78)B060-20160331$$kB060$$lMolekulare Genetik$$x4
000128762 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x5
000128762 980__ $$ajournal
000128762 980__ $$aVDB
000128762 980__ $$aI:(DE-He78)L401-20160331
000128762 980__ $$aI:(DE-He78)L101-20160331
000128762 980__ $$aI:(DE-He78)L501-20160331
000128762 980__ $$aI:(DE-He78)B062-20160331
000128762 980__ $$aI:(DE-He78)B060-20160331
000128762 980__ $$aI:(DE-He78)G380-20160331
000128762 980__ $$aUNRESTRICTED